FORREST WATKINS: Open Payments
NPI 1407233158 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,131 in 66 payments from 10 companies in 2025. Trend: 2023 $826 · 2024 $984 · 2025 $1,131
Food & beverage: $1,131
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 15 | $267 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $171 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $146 |
| Amgen Inc. | 9 | $146 |
| Novartis Pharmaceuticals Corporation | 8 | $139 |
| AstraZeneca Pharmaceuticals LP | 7 | $109 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 3 | $50 |
| Edwards Lifesciences Corporation | 1 | $27 |
| LANTHEUS MEDICAL IMAGING, INC. | 1 | $15 |
Products named: VYNDAQEL, Kerendia, JARDIANCE, REPATHA, LEQVIO, FARXIGA, ELIQUIS, CAMZYOS.
Industry payments across AL — which companies pay providers there.
